Form 4: Moderna Chief Legal Officer Shannon Klinger Executes Stock Transactions

Moderna's Chief Legal Officer, Shannon Klinger, acquired and disposed of company stock, including shares to cover tax obligations related to vesting restricted stock units.

Summary

• Shannon Klinger, Chief Legal Officer of Moderna, engaged in stock transactions on December 6th and December 9th, 2024.
• On December 6th, 1,138 shares of common stock were acquired through the vesting of restricted stock units (RSUs).
• Also on December 6th, 1,138 restricted stock units were converted to common stock.
• On December 9th, 529 shares were sold at a price of $44.683 per share.
• The sale of 529 shares was to cover tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Ms. Klinger beneficially owns 20,446 shares of Moderna common stock.

Sentiment

Score: 6

Explanation: The document reflects routine insider trading activity related to equity compensation. It is neither particularly positive nor negative, but rather a standard disclosure.

Positives

• The vesting of restricted stock units indicates that Ms. Klinger is meeting performance or time-based vesting requirements.

Risks

• The sale of shares to cover tax obligations could be perceived negatively by some investors, although it is a standard practice.

Industry Context

Insider trading activity is a normal part of corporate operations, especially for companies that use equity compensation. This filing is a routine disclosure of such activity.

Comparison to Industry Standards

• The transactions are typical for executives who receive stock-based compensation.
• Many companies, such as Pfizer (PFE) and BioNTech (BNTX), also have executives who regularly file Form 4s for similar transactions.
• The 'sell to cover' mechanism is a common practice to manage tax obligations related to equity awards.

Stakeholder Impact

• The transactions have a minimal impact on stakeholders as they are routine and do not indicate any significant change in the company's operations or financial health.

Key Dates

Keywords

Moderna, MRNA, Shannon Klinger, Chief Legal Officer, stock transaction, restricted stock units, RSU, insider trading, Form 4, equity compensation